Key result
Enoxaparin has a safety profile and clinical efficacy comparable to unfractionated heparin in acute coronary syndrome, offering simpler administration without routine coagulation monitoring.
Why the study?
Does enoxaparin offer advantages compared to unfractionated heparin in the management of patients with acute coronary syndrome?
Does enoxaparin offer advantages compared to unfractionated heparin in the management of patients with acute coronary syndrome?
Enoxaparin is a practical and effective alternative to unfractionated heparin in STEMI, and should be used in NSTEMI when fondaparinux is unavailable.
No takes yet. Share an insight, caveat, or question.
Enoxaparin may be preferred over UFH in ACS; leaves open optimal switching and contemporary PCI strategies.
Krikunova et al. (2018) conducted a review in Acute coronary syndrome (ACS). Enoxaparin vs. Unfractionated heparin was evaluated. Enoxaparin has a safety profile and clinical efficacy comparable to unfractionated heparin in acute coronary syndrome, offering simpler administration without routine coagulation monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: